Comparative Pharmacology
Head-to-head clinical analysis: TAZICEF versus ZEVTERA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAZICEF versus ZEVTERA.
TAZICEF vs ZEVTERA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftazidime is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3, leading to cell lysis and death.
Ceftobiprole, the active moiety of ZEVTERA, is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), including PBP2a in methicillin-resistant Staphylococcus aureus (MRSA), leading to cell death.
2 g intravenously every 8 hours for serious infections; 1 g intravenously every 8 hours for uncomplicated infections.
400 mg intravenously every 8 hours
None Documented
None Documented
2 hours (prolonged to 4-12 hours in renal impairment; anuria: 20-30 hours).
Terminal elimination half-life is approximately 3.5 hours in patients with normal renal function. In moderate renal impairment (CrCl 30-50 mL/min), half-life extends to ~6 hours, requiring dose adjustment.
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal <10%.
Approximately 70% of the dose is excreted unchanged in urine, with 20% recovered in feces via biliary elimination. Minor route: <5% as metabolites.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic